TAP Partner News During ASCO: June 2022
TAP Partner News During ASCO: June 2022
Biotheryx to Present Preclinical Data for Its Dual Protein Degrader BTX-1188 at the 2022 American Society of Clinical Oncology Annual Meeting
SAN DIEGO, CA. May 26, 2022 — Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) in areas of high unmet medical need, today announced that its abstract highlighting supportive preclinical data for its lead asset BTX-1188, a potentially first-in-class, dual protein degrader of GSPT1 and IKZF1/3, will be presented in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022, in Chicago, Illinois and virtually.
Carisma Therapeutics to Present Latest Data from Phase 1 Clinical Trial of Engineered Macrophage Therapy at 2022 ASCO Annual Meeting
PHILADELPHIA, PA – May 26, 2022 – Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced two presentations including findings of its lead candidate, CT-0508, accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, June 3-7.
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
Heidelberg, Germany, May 26, 2022 – Affimed N.V. (Nasdaq: AFMD), (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that three abstracts of clinical trial designs of its AFM24 innate cell engager (ICE®) have been published and will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on June 3-7, 2022 in Chicago, IL.
Gilead to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
FOSTER CITY, CA, May 17, 2022 - Gilead Sciences, Inc. (Nasdaq: GILD) announced that 3 abstracts for TAP-supported magrolimab, an investigational anti-CD47 antibody, including two poster discussions, will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. These data highlight promising data in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO
DUBLIN, May 12, 2022 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present abstracts on Vyxeos®/Vyxeos® Liposomal (daunorubicin and cytarabine), also known as JZP351 at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 – June 7, 2022.
Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Krakow, Poland – April 27, 2022 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced project updates from its most advanced oncology program RVU120 and a selective PIM/FLT3 inhibitor SEL24 (MEN1703) will be made available at the 2022 ASCO Annual Meeting, taking place June 3-7 in Chicago, IL, U.S.